Targeted Protein Degradation for Age-Related Disease

From Inhibition to Induced Removal

Conventional small molecules usually work by occupying a functional site and reducing a protein's activity while the drug remains bound. A targeted degrader instead creates a new interaction between a protein of interest and cellular disposal machinery. In the best-studied format, a proteolysis-targeting chimera, or PROTAC, binds both the target and an E3 ubiquitin ligase; ubiquitin is transferred to the target, which is then recognized by the proteasome. [1] [2]

Because one degrader molecule can participate in repeated degradation cycles, protein removal can be event-driven rather than sustained by continuous target occupancy. Experiments with small-molecule PROTACs demonstrated substantial, selective protein depletion at nanomolar concentrations and target knockdown in mouse tumour xenografts, establishing the mechanism without showing that the same pharmacology will apply to every protein or tissue. [3]

Why Age-Related Disease Is a Distinct Test Case

Several age-related diseases involve proteins whose abundance, conformation, location, or persistence contributes to pathology. Examples under investigation include abnormal tau in tauopathies and BCL-xL-dependent survival in some senescent cells. These are disease-specific hypotheses: removing one pathological protein is not equivalent to reversing biological ageing, and the benefit depends on whether that protein is causally important in the relevant cells. [4] [8]

Degradation may offer a conceptual advantage when a protein has important scaffolding functions, lacks a conventional inhibitory pocket, or needs to be removed rather than transiently silenced. It can also remove several functions of the same protein at once. That breadth is a possible liability as well as an advantage because normal functions may be lost alongside the disease-associated activity. [1] [9]

Major Degradation Platforms

These platforms are not interchangeable. Proteasomes mainly handle proteins that can be ubiquitinated and unfolded, whereas lysosomal routes can accommodate extracellular cargo, membrane proteins, or larger assemblies depending on the platform. The expression and activity of the recruited ligase, receptor, or autophagy machinery can therefore determine where a degrader works. [1] [5] [6]

Protein Aggregation and Neurodegeneration

Tauopathies provide a direct test of whether a disease-associated protein can be selectively removed. The degrader QC-01-175 linked a tau-binding ligand to a cereblon-binding ligand and reduced tau and phosphorylated tau in neurons derived from people with frontotemporal dementia. In those cell models, degradation depended on cereblon and the proteasome, and treatment reduced a measured vulnerability to cellular stress. [4]

Autophagy-directed chemistry has been explored for cargo that may be difficult for proteasomal systems. An AUTOTAC platform study used bifunctional molecules that connect targets to p62 and reported degradation of several proteins, including pathological tau species; a tau-directed compound also reduced pathology in a transgenic mouse model. This remains preclinical evidence from engineered systems, not evidence of efficacy in people with Alzheimer's disease or another tauopathy. [5]

Brain delivery adds a separate constraint. A degrader must reach the relevant brain regions and cell types, retain sufficient exposure, engage the intended protein species, and recruit functioning disposal machinery without removing physiologically useful protein elsewhere. Success in cultured neurons does not by itself answer those distribution and safety questions. [1] [4] [9]

Senescent-Cell Survival as a Degradation Target

Some senescent cells depend on anti-apoptotic BCL-2-family proteins, making BCL-xL a candidate senolytic target. Direct BCL-xL inhibition can also injure platelets, which rely on that protein. PZ15227 was designed to recruit BCL-xL to cereblon, an E3-ligase component expressed at low levels in platelets, with the aim of making degradation more active in senescent cells than in platelets. [7] [8]

In naturally aged mice, PZ15227 cleared senescent cells and improved measures of tissue stem and progenitor-cell function without the severe thrombocytopenia associated with the comparator inhibitor in that study. The experiment illustrates how differential E3-ligase expression might create cell selectivity, but mouse findings do not establish an acceptable therapeutic window, durable benefit, or clinical effectiveness in older humans. [8]

What Human Studies Establish

Human testing of heterobifunctional degraders has established that substantial target depletion is pharmacologically possible. In a phase 1 study, the IRAK4 degrader KT-474 reduced IRAK4 in blood and affected skin, with biomarker changes in participants with hidradenitis suppurativa or atopic dermatitis. The trial was designed primarily around safety, tolerability, pharmacokinetics, and pharmacodynamics and does not validate targeted degradation for ageing or neurodegeneration. [10]

The clinical result is relevant mainly as platform evidence: an orally administered degrader reached people, lowered its intended protein, and produced measurable downstream effects. Each proposed age-related indication still requires its own evidence for target causality, delivery, dose, duration, clinical outcome, and long-term safety. [9] [10]

Translational Constraints

• Target choice: efficient degradation is useful only if lowering the selected protein changes the disease process without unacceptable loss of normal function. [1] [9]
• Tissue and cell selectivity: degrader exposure and expression of the recruited E3 ligase or lysosomal receptor vary across biological contexts. [6] [8]
• Molecular properties: bifunctional degraders are often larger and more structurally complex than conventional small molecules, which can complicate permeability, oral exposure, and brain penetration. [9]
• Ternary-complex biology: binding the target and ligase separately does not guarantee productive ubiquitination; geometry, cooperativity, available lysines, and subcellular location influence degradation. [1] [3]
• Resistance and adaptation: changes in the target, recruited machinery, or drug transport can reduce degrader activity, as described in experimental and clinical-development literature. [1] [9]

Evidence Quality and Open Questions

Evidence is strong that induced proximity can produce selective protein degradation and that target depletion can occur in humans for at least some proteins. Evidence for age-related disease is earlier: tau studies are primarily cellular or animal work, and the senolytic PROTAC evidence comes from preclinical models. No single result supports targeted degradation as a general intervention against ageing. [4] [5] [8] [10]

Important questions include which disease-associated protein species should be removed, whether partial or intermittent depletion is sufficient, how target engagement can be measured in inaccessible tissues, and whether long-term manipulation of proteasomal or lysosomal routing produces compensatory effects. These questions require target-specific pharmacology and disease-relevant outcomes rather than protein loss alone. [1] [9]

Summary

Targeted protein degradation changes the therapeutic question from how to inhibit a protein to whether that protein can be selectively removed. Proteasomal and lysosomal platforms have expanded the range of experimental cargo, and studies involving tau, senescent-cell survival, extracellular proteins, and inflammatory signalling provide distinct forms of proof of concept. For age-related disease, the central uncertainties are not only whether degradation occurs, but where it occurs, which protein species are lost, whether function improves, and whether the effect remains safe over clinically relevant periods. [4] [5] [6] [8] [10]

References

1. Tsai, J. M. et al. (2024). Targeted protein degradation: from mechanisms to clinic. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/s41580-024-00729-9
2. Sakamoto, K. M. et al. (2001). Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.141230798
3. Bondeson, D. P. et al. (2015). Catalytic in vivo protein knockdown by small-molecule PROTACs. Nature Chemical Biology. https://doi.org/10.1038/nchembio.1858
4. Silva, M. C. et al. (2019). Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. eLife. https://doi.org/10.7554/eLife.45457
5. Ji, C. H. et al. (2022). The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system. Nature Communications. https://doi.org/10.1038/s41467-022-28520-4
6. Banik, S. M. et al. (2020). Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. https://doi.org/10.1038/s41586-020-2545-9
7. Chang, J. et al. (2016). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine. https://doi.org/10.1038/nm.4010
8. He, Y. et al. (2020). Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nature Communications. https://doi.org/10.1038/s41467-020-15838-0
9. Békés, M., Langley, D. R. and Crews, C. M. (2022). PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-021-00371-6
10. Ackerman, L. et al. (2023). IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02635-7